Twice‑yearly injectable HIV regimen treatment demonstrates strong efficacy and safety in Phase 2 trial

AI Summary

A Phase 2 trial published in The Lancet Microbe demonstrates that a twice-yearly injectable HIV regimen combining lenacapavir, teropavimab, and zinlirvimab achieves high viral suppression rates with a favorable safety profile at 26 weeks. Led by Dr. Joe Eron at the UNC Institute for Global Health and Infectious Diseases, the findings could mark a breakthrough toward the first complete long-acting HIV treatment requiring only two doses per year. This represents a significant advancement in HIV management and patient adherence.

A new study published in The Lancet Microbe reports the first twice-yearly injectable HIV treatment regimen—combining lenacapavir, teropavimab, and zinlirvimab—has achieved high rates of viral suppression and demonstrated a favorable safety profile at 26 weeks. Led by Joe Eron, MD, a researcher with the UNC Institute for Global Health and Infectious Diseases, the findings mark a significant milestone toward what could become the first complete long-acting HIV regimen requiring dosing only twice per year.